reference/25501593

http://rdf.ncbi.nlm.nih.gov/pubchem/reference/25501593

Outgoing Links

Predicate	Object
contentType	Clinical Trial, Phase I\|Journal Article\|Research Support, Non-U.S. Gov't
endingPage	203
issn	0030-2414 1423-0232
issueIdentifier	3-4
pageRange	197-203
publicationName	Oncology
startingPage	197
bibliographicCitation	Kalykaki A, Vamvakas L, Agelaki S, Kalbakis K, Vardakis N, Sfakiotaki G, Ignatiadis M, Saridaki Z, Karampeazis A, Karabeazis A, Mavroudis D, Georgoulias V. A dose escalation study of gemcitabine plus pemetrexed administered biweekly in patients with solid tumors. Oncology. 2006;71(3-4):197–203. doi: 10.1159/000106069. PMID: 17641541.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_75852d7ccb48a94a95e9f094c668baf7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_405dfc9a88899ff47c2eb1a59b047ae3 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_ea3ca2fbe612dbda4c01ef9af734e9e0 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_71dd4d7de08b1632a7743b632e97938c http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_2df0091d1b12451a1833564525cde2a9 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_70d4da00031b6333960268055e16f9b7 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_df1c4f29ae801a5d1d79b7fe7c8375ad http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_f9e27d644c6f4b5f3debb57368e8f342 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e8629aef425c4db8482cc9a9ff302a6f http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_1c878846a422b8dcde15050922b09492 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_03137deef775148953f604fa2c58cb70 http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_abc76e3d6079cfcaf67ac95e45dbb3e5
date	2006
identifier	https://doi.org/10.1159/000106069 https://pubmed.ncbi.nlm.nih.gov/17641541
isPartOf	http://rdf.ncbi.nlm.nih.gov/pubchem/journal/6265 https://portal.issn.org/resource/ISSN/0030-2414 https://portal.issn.org/resource/ISSN/1423-0232
language	English
source	https://www.crossref.org/ https://pubmed.ncbi.nlm.nih.gov/
title	A Dose Escalation Study of Gemcitabine plus Pemetrexed Administered Biweekly in Patients with Solid Tumors
discusses	http://id.nlm.nih.gov/mesh/M0009679 http://id.nlm.nih.gov/mesh/M0009376 http://id.nlm.nih.gov/mesh/M0227083 http://id.nlm.nih.gov/mesh/M000754277 http://id.nlm.nih.gov/mesh/M0005997
hasPrimarySubjectTerm	http://id.nlm.nih.gov/mesh/D006147Q000031 http://id.nlm.nih.gov/mesh/D005971Q000008 http://id.nlm.nih.gov/mesh/D003841Q000031 http://id.nlm.nih.gov/mesh/D000971Q000627
hasSubjectTerm	http://id.nlm.nih.gov/mesh/D020714 http://id.nlm.nih.gov/mesh/D006147Q000008 http://id.nlm.nih.gov/mesh/D003841Q000008 http://id.nlm.nih.gov/mesh/D000093542 http://id.nlm.nih.gov/mesh/D006147Q000009 http://id.nlm.nih.gov/mesh/D000369 http://id.nlm.nih.gov/mesh/D008875 http://id.nlm.nih.gov/mesh/D005971Q000009 http://id.nlm.nih.gov/mesh/D008297 http://id.nlm.nih.gov/mesh/D003841Q000009 http://id.nlm.nih.gov/mesh/D000328 http://id.nlm.nih.gov/mesh/D000068437 http://id.nlm.nih.gov/mesh/D000971Q000008 http://id.nlm.nih.gov/mesh/D009369Q000188 http://id.nlm.nih.gov/mesh/D005260 http://id.nlm.nih.gov/mesh/D006801 http://id.nlm.nih.gov/mesh/D000368
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8661 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID135410875 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8607 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID8752 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11449 http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID11445 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID60750

Incoming Links

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129439837 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID129221764 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID135945851 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID127639621

Total number of triples: 68.